Induction of cyclooxygenase-2 (COX-2) in the renal pelvic wall increases prostaglandin E 2 (PGE 2 ) leading to stimulation of cAMP production which results in substance P (SP) release and activation of renal mechanosensory nerves. The subtype of PGE receptors involved, EP2 and/or EP4, was studied by immunohistochemistry and renal pelvic administration of agonists and antagonists of EP2 and EP4 receptors. EP4 receptor-like immunoreactivity (LI) was colocalized with calcitonin gene-related peptide (CGRP)-LI in dorsal root ganglia (DRGs) at Th 9 -L 1 and in nerve terminals in the renal pelvic wall. Th 9 -L 1 DRG neurons also contained EP3 receptor-LI and COX-2-LI, each of which was colocalized with CGRP-LI in some neurons. No renal pelvic nerves contained EP3 receptor-LI and only very few nerves COX-2-LI. The EP1/EP2 receptor antagonist AH6809, 20 µM, had no effect on SP release produced by PGE 2 , 0.14 µM, from an isolated rat renal pelvic wall preparation. However, the EP4 receptor antagonist L-161,982, 10 µM, blocked the SP release produced by the EP2/EP4 receptor agonist butaprost, 10 µM, 12 ± 2 vs. 2 ± 1 and PGE 2 , 9 ± 1 vs. 1 ± 0 pg/min. The SP release by butaprost and PGE 2 was similarly blocked by the EP4 receptor antagonist AH23848, 30 µM. In anesthetized rats, the afferent renal nerve activity (ARNA) responses to butaprost, 700 ± 100, and PGE 2 , 780 ± 100 %⋅sec (area under the curve of ARNA vs. time) were unaffected by renal pelvic perfusion with AH6809. However, 1 µM L-161,982 and 10 µM AH23848 blocked the ARNA responses to butaprost by 94 ± 5 and 78 ± 10%, respectively, and to PGE 2 by 74 ± 16 and 74 ± 11%, respectively. L-161,982 also blocked the ARNA response to increasing renal pelvic pressure 10 mmHg, 85 ± 5%. Conclusion: PGE 2 increases renal pelvic release of substance P and ARNA by activating EP4 receptors on renal sensory nerve fibers.
INTRODUCTION
Prostaglandin E 2 (PGE 2 ) is the major product of cyclooxygenase (COX)-induced metabolism of arachidonic acid in the kidney (3) and plays a critical role for normal renal function by its effects on renal microvasculature and urinary water and sodium excretion. In addition to its direct effects on tubular sodium and water reabsorption, our studies indicate that PGE 2 also modulates urinary sodium excretion by its effects on afferent renal nerves (25,27,29).
The majority of the afferent renal nerves containing substance P and calcitonin gene-related peptide (CGRP) are located in the renal pelvic wall (28,33,54). These nerves are activated by increases in renal pelvic pressure of a magnitude, ≥3 mmHg (26,30), seen during moderate volume expansion. The increase in afferent renal nerve activity (ARNA) produced by the increased renal pelvic pressure leads to a reflex decrease in efferent renal sympathetic nerve activity (ERSNA) and a diuresis and natriuresis, i.e., a renorenal reflex response (31).
Among the various mechanisms activated by stretching the renal pelvic wall are induction of COX-2 leading to increased renal pelvic synthesis of PGE 2 (25, 27, 29) . PGE 2 increases the release of substance P via activation of the cAMP -protein kinase A transduction pathway (25). Substance Indomethacin was dissolved together with Na 2 CO 3 (2:1 weight ratio) in HEPES buffer. Butaprost, methyl acetate solution evaporated, was dissolved in DMSO and further diluted in the various incubation buffers (in vitro studies) or 0.15 M NaCl (in vivo studies), final DMSO concentration being 0.1%. All other agents were dissolved in the various incubation buffers (in vitro studies) or 0.15 M NaCl (in vivo studies).
Analytical Procedures
Right urinary sodium excretion, measured in two groups see below, was expressed per gram kidney weight. Urinary sodium concentrations were determined with a flame photometer.
Substance P in the incubation medium was measured by ELISA, as previously described in detail (21-29).
Statistical Analysis
In vitro, the release of substance P during the experimental period was compared with that during the control and recovery periods using Friedman 2-way analysis of variance and shortcut analysis of variance. The Wilcoxon matched-pairs signed-rank test was used to compare the increases in substance P release from ipsilateral and contralateral renal pelvises. In vivo, the ARNA responses to PGE 2 , butaprost and renal pelvic pressure were calculated as the area under the curve (AUC) of ARNA vs. time, where ARNA was expressed as percentage of its baseline value during the bracketing control and recovery periods. Friedman 2-way analysis of variance and shortcut analysis of variance were used to determine the effects of the various treatments on the ARNA responses within each rat. A significance level of 5% was chosen. Data in text and figures are expressed as means ± SE (45,48).
RESULTS

Immunohistochemistry
Localization of EP4 receptors in renal tissue and DRG. Many neuronal cell bodies in Th 9
DRGs were labeled with the antibody to EP4 receptors (Fig. 1a) . The EP4 receptor-LI was blocked by adsorption with the peptide (Fig. 1b) . Double-labeling experiments showed that some of the neuronal cell bodies that were EP4 receptor-immunoreactive (ir) and also contained CGRP-LI ( Fig.   1c-e) . A similar distribution of EP4 receptor-and CGRP-LI was found in all Th 9 -L 1 DRGs studied.
Further, strong labeling with the EP4 receptor antibody was observed in nerve fibers in the renal pelvic wall (Fig. 1g) . This staining was also blocked by adsorption with the peptide (Fig 1h) . Doublelabeling showed that the EP4 receptor-ir nerves in the pelvic wall also contained CGRP-LI (Fig. 1i,j &f). Higher magnification of a thin nerve bundle in the renal pelvic wall revealed EP4 receptor-LI in and adjacent to CGRP-ir nerve fibers (Fig. 1f) . Likewise, in thicker nerve bundles in the renal pelvic area, EP4 receptor-LI was found in CGRP-ir nerve fibers (Fig. 2a-c) . However, there were also EP4 receptor-ir nerve fibers that did not contain CGRP-LI. Double-labeling kidney sections with antibodies to the EP4 receptors and TH, a marker for sympathetic nerves, showed some nerve bundles in the renal pelvic wall containing both receptor and enzyme but also single-labeled fibers (Fig. 2d-f ).
The EP4 receptor antibody also labeled thin nerve fibers along arterioles close to glomeruli, among vasa recta bundles and in arterial walls and veins throughout the kidney (data not shown). EP4 receptor-LI was also found in tissue surrounding the arteries in the renal pelvic area. Most of the EP4 receptor-ir nerve bundles and nerve terminals in non-pelvic renal tissue were also TH-ir.
Furthermore, EP4 receptor staining was also found in the apical membrane in cortical tubular structures adjacent to the glomeruli. All EP4 receptor staining was prevented by preadsorption with the peptide used for immunization.
Localization of EP3 receptors in renal tissue and DRG.
In agreement with previous studies (40), EP3 receptor-LI was found in DRGs (Fig. 3a) . Further, our studies showed that a small portion of the neuronal cell bodies in Th 9 -L 1 DRGs contained both EP3 receptor-and CGRP-LI (Fig. 3a-c) .
Therefore, we examined whether renal pelvic sensory nerve fibers contained EP3 receptor-LI.
However, no EP3 receptor-LI was found in the CGRP-ir nerve fibers in the pelvic wall ( Fig. 3d-f) .
Also, EP3 receptor-LI was not found on TH-ir nerve fibers in the renal tissue (data not shown).
Instead at the renal pelvic tip, strong labeling with the EP3 receptor antibody was observed in fibers that were also labeled with an α-SM actin antibody, a marker for smooth muscle fibers (Fig. 3g-i ).
In agreement with in situ hybridization studies (5,47), there was strong labeling with the EP3 receptor antibody in macula densa cells (data not shown) and tubular structures in the inner stripe of the outer medulla and papilla (Fig. 4c&e) . The EP3 receptor antibody also labeled the apical/brush border membrane in proximal tubules (Fig. 4f) . The EP3 receptor staining of the muscle fibers in the pelvic tip, the tubular structures in the inner stripe of outer medulla and the proximal tubular apical/brush border were blocked by adsorption with the peptide (Fig. 4b&d) .
Localization of COX-2 in renal tissue and DRG. Because PGE 2 is known only to act in the vicinity of its production, we examined whether COX-2 is distributed in DRGs and in or close to the renal sensory nerves. Numerous neuronal cell bodies in Th 9 -L 1 DRGs were labeled with the antibody to COX-2 (Fig. 5a ). Double-labeling showed many more neuronal cell bodies labeled with COX-2 antibody (Fig. 5a ) than the CGRP antibody (Fig. 5b) . However, many CGRP-ir cell bodies also contained COX-2. Blocking the COX-2 antibody with the immunogenic peptide abolished the labeling (Fig. 5c ).
In agreement with previous studies (19), COX-2-LI was localized in the macula densa cells and renal medullary interstitial cells (not shown). COX-2-LI was also observed in the uroepithelium (Fig. 5d) . Only very few sensory nerve fibers in the renal pelvic wall were labeled with the COX-2 antibody (Fig. 5d) . However, COX-2-LI was found in some nerve bundles along the renal pelvic wall (Fig, 5f ). In adjacent sections, the same nerve bundle also contained EP4 receptor-LI (Fig. 5g) .
In Vitro Studies
Effects of an EP1/EP2 receptor antagonist on PGE 2 -mediated substance P release. Because PGE 2 increases the renal pelvic release of substance P by stimulating cAMP production in the renal pelvic wall (25), we tested whether AH6809, an EP receptor antagonist with equal affinity for EP1 and EP2 receptors and much greater affinity for EP2 than EP4 receptors (2,53) would alter the substance P release produced by PGE 2 . However, our data show that the increase in renal pelvic release of substance P produced by PGE 2 was unaltered by the presence of AH6809 in the incubation bath (Fig. 6) .
Effects of EP4 receptor antagonists on substance P release. Butaprost, an agonist with a higher affinity for EP2 than EP4 receptors (2,10,41) activates renal sensory nerves by increasing cAMP activity, similar to PGE 2 (25). However, the concentration of butaprost required was >4 :M (25), suggesting that this effect may not be related only to activation of EP2 but also EP4 receptors.
This hypothesis was tested by examining the effects of two EP4 receptor antagonists with different molecular structures. As shown in Figure 7 , incubating the renal pelvises with the selective EP4 receptor antagonist L-161,982 abolished the increases in renal pelvic substance P release produced by either PGE 2 or butaprost. Likewise, the EP4 receptor antagonist AH23848 blocked the renal pelvic release of substance P produced by PGE 2 and butaprost (Table 1) . Importantly, the PGE 2 -mediated release of substance P was not affected by L-161,983, the inactive enantiomer of L-161,982 (Table   2 ).
In Vivo Studies Effects of an EP1/EP2 receptor antagonist on the ARNA responses to PGE 2 and butaprost.
Renal pelvic administration of PGE 2 and butaprost results in increases in ARNA that are of a similar magnitude and blocked by inhibiting adenylyl cyclase (25). PGE 2 , 0.14 :M, and butaprost, 10 :M, produced an increase in ARNA that was of a similar magnitude ( Fig. 8 ) and duration, 46 ± 8 and 34±3 sec, respectively. There were no significant differences among the increases in ARNA produced by PGE 2 and butaprost before and during renal pelvic perfusion with AH6809. Arterial pressure, 111 ± 3 mmHg, and heart rate, 349 ± 15 beats/min, were unaltered by PGE 2 , butaprost and AH6809. 2 and butaprost. Because our in vivo studies suggested that activation of EP2 receptors did not contribute to the ARNA responses to PGE 2 and butaprost and our in vitro studies suggested that PGE 2 and butaprost increased substance P release by activation of EP4 receptors, we examined whether the ARNA responses to renal pelvic administration of PGE 2 and butaprost were blocked by renal pelvic perfusion with the EP4 receptor antagonists L-161,982 and/or AH23848. As shown in Fig. 9 and Table 3 , renal pelvic perfusion with either L-161,982 or AH23848, produced marked blockade of the ARNA responses to both PGE 2 and butaprost. Neither L161,982 nor AH23848 altered arterial pressure, 110 ± 3 and 109 ± 1 mm Hg, or heart rate, 353 ± 11 and 345 ± 13 beats/min, in the two groups, respectively. Time control experiments showed that repeated administration of PGE 2 and butaprost resulted in (Table 3) .
Effects of EP4 receptor antagonists on the ARNA responses to PGE
Effects of an EP4 receptor antagonist on the ARNA responses to increased renal pelvic
pressure. Because the increase in ARNA produced by increased renal pelvic pressure involves increased renal PGE 2 syntheses and stimulation of cAMP production, and blocking renal EP4 receptors reduces the ARNA response to PGE 2 , we examined whether renal pelvic perfusion with the EP4 receptor antagonist L-161,982 would alter the ARNA responses to increasing renal pelvic pressure. Elevating renal pelvic pressure 9.8 ± 0.2 mmHg increased ipsilateral ARNA ( 
DISCUSSION
The results of these studies show numerous EP4 receptor-LI containing thin nerve fibers in the renal pelvic wall. The majority of these nerve fibers also contained CGRP-LI. Since these two markers were also colocalized in Th 9 -L 1 DRG neurons, these findings suggest that EP4 receptor-LI is present in the majority of the sensory nerves in the renal pelvic wall. Studies using an isolated renal pelvic wall preparation showed that the increases in substance P release produced by PGE 2 and butaprost were blocked by the EP4 receptor antagonists AH23484 and L-161,982 but not by AH6809, an EP1/EP2 receptor antagonist. Likewise, our in vivo studies showed that the ARNA responses to renal pelvic administration of PGE 2 and butaprost were blocked by renal pelvic perfusion with AH23484 and L-161,982 but not by AH6809. Importantly, renal pelvic perfusion with L-161,982 also blocked the ARNA response to increased renal pelvic pressure. Taken together, our studies suggest that PGE 2 activates mechanosensory nerves by stimulating EP4 receptors located on or adjacent to the sensory nerve fibers in the renal pelvic wall.
EP4 Receptors in DRG and Neural and Non-Neural Renal Tissue.
Due to our previous studies showing that PGE 2 increases substance P release and activates renal mechanosensory nerves via stimulation of cAMP production (25), we reasoned that the EP receptor subtype involved was either of the EP2 or EP4 subtypes (10). Preliminary studies using an antibody raised against the human-EP2 receptor (39) failed to label any structures in the rat kidney.
Although we cannot exclude that the human EP2 receptor antibody does not recognize rat EP2 receptors, a likely explanation may also be the very low expression of EP2 receptors in normal rat kidneys (20). On the other hand, EP4 receptors are more widespread throughout the body, including the kidney (6,20,41,43). EP4 receptors have been found in hypothalamus and lower brain stem (41) and PGE 2 acting via EP4 receptors has an excitatory effect on parasympathetic preganglionic spinal neurons innervating the pelvic visceral organs (38). Of particular importance for the current studies are the findings showing that EP4 mRNA is expressed in DRGs (41). PGE 2 -mediated activation of EP4 receptors in cultured DRGs increases cAMP activity (46). In agreement with these findings, our present studies show EP4 receptor-LI in Th 9 -L 1 DRGs. Furthermore, the current data show that DRG neurons as well as renal pelvic nerve terminals contain both EP4 receptor-and CGRP-LI suggesting that EP4 receptors are present in peripheral renal sensory nerves. These EP4 receptor-ir nerve fibers were distributed in the uroepithelium and in the muscle layer of the renal pelvic wall. Whether these EP4 receptors are derived from the DRGs and/or from a local synthesis, suggested from the demonstrated strong EP4 mRNA signal in the uroepithelium (6), is currently not known.
EP4 receptor-LI was also found in thin nerve fibers along glomerular arterioles, among vasa recta bundles and in vessel walls throughout the kidney. Because the majority of these fibers also contained TH-LI, these findings suggest the presence of EP4 receptors on sympathetic renal nerves The EP4-receptor labeling of apical membrane of cortical structures adjacent to glomeruli in the current study is consistent with the marked expression of EP4 receptor mRNA in rat distal tubules
The labeling of all nerve fibers in DRG and renal tissue was specific to the EP4 receptor antibody in the sense that it was abolished by preadsorption with the immunogenic peptide (see also 39).
Previous immunohistochemistry studies in human unfixed renal tissue have shown EP4 receptor-LI in arterial muscle wall (39,49). This was not observed in the present study. The reason for this apparent discrepancy is not known but could be related to different treatment of the tissue, unfixed vs. fixed, and species studied, human vs. rat tissue.
EP3 receptors in Renal Non-neural and Neural Tissue and DRG.
Because of the considerable evidence for EP3 receptors in the areas of the central nervous DRGs, suggest that these EP3 receptor-ir neurons project to other organs than the kidney, are localized specifically in the cell body and the central endings of the sensory nerves (40), or centrifugally transported at such low levels that they cannot be detected with our methodology.
COX-2 in Renal Non-Neural and Neural Tissue and DRG
COX-2 is constitutively expressed and widely distributed in the central nervous system (4) including the superficial dorsal horn of the spinal cord (52). However, several studies have reported lack of COX-2 labeling in DRGs in normal rats (9,50,51). In contrast, the current study shows intense COX-2 labeling of neuronal cell bodies in Th 9 -L 1 DRGs in normal rats. The labeling was specific to the COX-2 antibody in the sense that it was abolished by preadsorption with the immunogenic peptide. The apparent differences in the results between the current and previous studies may be explained by the DRGs studied. Whereas, the current study concerned Th 9 -L 1 DRGs, previous studies have focused on more caudal lumbar DRGs (9,51). The current study further showed that many of the COX-2-ir neurons in the DRGs also contained CGRP-LI suggesting that COX-2 is present in sensory neurons.
The marked inhibition of the ARNA response to increased renal pelvic pressure produced by renal pelvic administration of COX-2 inhibitors (27) suggests that COX-2 in the renal pelvic wall contributes importantly to the activation of renal pelvic mechanosensory nerves. Due to its rapid metabolism, the actions of PGE 2 on its receptors should occur in the vicinity of its site of synthesis.
Interestingly, COX-2 has been found to be colocalized with EP4 receptors in the vasculature in human kidneys (49). Thus, we speculated that COX-2 may be located in or close to the renal pelvic sensory nerves. However, the current study showed only very few thin COX-2-ir nerve fibers in the pelvic wall. This relative absence of COX-2-LI despite its presence in many CGRP-LI containing neurons in Th 9 -L 1 DRGs and in nerve bundles along the renal pelvic wall may be explained by the sensitivity of our immunohistochemistry being too low to detect the enzyme in the sensory nerve terminals, as discussed above. Whereas the presence of COX-2-and EP4 receptor-LI in nerve bundles along the renal pelvic wall suggests PG synthesis in or in close vicinity to the renal nerve fibers, the strong COX-2 mRNA signal in the uroepithelium and renal pelvic muscle layer (27) suggests that a large portion of PGE 2 synthesis occurs in the tissue surrounding the renal sensory nerves.
However, our findings do not exclude the possibility that PGE 2 involved in the activation of renal pelvic sensory nerves may, at least in part, be derived from COX-1 present in or close to the these sensory nerves. COX-1 is present in renal tissue (8,49). Although there is currently little anatomical evidence for COX-1 in renal pelvic tissue, our previous studies showing that the non-selective COX inhibitor indomethacin produced a more marked inhibition of renal sensory nerve activation than selective COX-2 inhibitors (27) may suggest that induction of both COX-1 and COX-2 contributes to the PGE 2 -mediated stimulation of renal sensory nerves.
Role of EP2 and EP4 Receptors in the Activation of Renal Sensory Nerves.
Butaprost, a selective EP2 receptor agonist at nanomolar concentrations, displays affinity for the EP4 receptors at micromolar concentrations (13,16). Because our previous studies showed that the renal sensory nerves were activated by butaprost at 10 µM but not 4 µM (25), we hypothesized that PGE 2 (and butaprost) activates renal pelvic sensory nerves by stimulating EP4 and not EP2 receptors. Examining the effects of various EP receptor antagonists on the responses to activation of renal sensory nerves both in vitro and in vivo confirmed our hypothesis. The EP1/EP2 receptor antagonist AH6809 (53) failed to attenuate the PGE 2 -mediated increase in substance P release from the isolated renal pelvises or the increases in ARNA produced by either PGE 2 or butaprost. On the other hand, the increases in substance P release and ARNA produced by PGE 2 and butaprost in vitro and in vivo, respectively, were abolished by AH23848, a selective but relatively weak EP4 receptor antagonist (10). Importantly, similar results were obtained with a more potent selective EP4 receptor antagonist of a different molecular structure, L-161,982 (34).
The PGE 2 -mediated substance P release is a crucial mechanism in the activation of renal mechanosensory nerves (25,27,29). Therefore, we also examined whether the increase in ARNA produced by elevated renal pelvic pressure is modulated by an EP4 receptor antagonist. Indeed, renal baseline substance P release, from 4.30 ± 0.5 to 4.4 ± 0.8 pg/min (n=8), from the isolated renal pelvic wall preparation. This was in marked contrast to the effects of PGE 2 , 0.14 µM, which increased baseline substance P release from the contralateral pelvis, from 4.9 ± 0.6 to 14.1 ± 1.5 pg/min (P<0.01). Further in vitro studies showed that sulprostone also did not alter the PGE 2 -mediated substance P release from the isolated renal pelvic wall. In agreement with our studies are studies in cultured DRGs which failed to show an effect of sulprostone on PGE 2 -mediated cAMP activity (43).
The lack of effects of sulprostone may be related to sulprostone being a non-selective agonist of EP1 receptors and EP3a, EP3b and EP3c receptors. On the other hand, the data may suggest relative absence of EP3 receptors modulating renal pelvic sensory nerves as suggested by our immunohistochemical studies.
Physiological Significance of the Renorenal Reflexes
The responsiveness of the afferent renal nerves is enhanced by high and suppressed by low sodium diet, suggesting that this reflex mechanism contributes to total body sodium and fluid volume balance by assisting in the excretion of sodium and water (24). This hypothesis was confirmed by our previous studies in dorsal rhizotomized rats. Interrupting the afferent renal nerve input to the spinal cord at Th 9 -L 1 results in salt sensitive hypertension (23). Thus during a high sodium intake, interruption of the afferent limb of the renorenal reflexes results in the development of increased arterial pressure, presumably to facilitate natriuresis and establishment of sodium balance. In view of the renorenal reflexes being impaired in rats fed fatty acid deficient diet (30), it is interesting that these rats become hypertensive when placed on a high sodium diet (11). Also, selective inhibition of renal medullary COX-2 activity results in salt sensitive hypertension (37). Further, the renorenal reflexes are impaired in spontaneously hypertensive rats (22) and rats with congestive heart failure F-00230-2004.R1 21 (26) suggesting that the decreased responsiveness of the renal sensory nerves may contribute to the increased ERSNA and sodium retention in these pathological conditions. In summary, the present study shows EP4 receptor-LI in CGRP-ir nerves in the renal pelvic wall and Th 9 -L 1 DRGs, suggesting the presence of this subtype of PGE receptors on renal pelvic sensory nerves. These findings are supported by our functional studies showing that the increases in substance P release and ARNA produced by PGE 2 were blocked by selective EP4 receptor antagonists but not by an EP2 receptor antagonist. Also, the EP4 receptor antagonist blocked the increases in ARNA produced by elevated renal pelvic pressure. Our immunohistochemical studies further showed the presence of COX-2-LI in the vicinity of EP4 receptor-ir nerves in the renal pelvic area suggesting the synthesis of PGE 2 close to EP4 receptors. On the other hand, there was no evidence for EP3 receptor-LI on or close to renal pelvic nerve fibers. Taken together, our data suggest that PGE 2 activates renal pelvic mechanosensory nerve fibers by stimulating EP4 receptors located on or in the vicinity of the renal pelvic sensory nerve fibers. Values are mean ± SE in pg/min. CNT, average of 4 control periods; REC, average of 4 recovery periods; ipsi, ipsilateral; contra, contralateral; * P<0.01 vs. average of CNT and REC. Substance P release, pg/min 
